» Sur le Web » Clinical Trials News From Medical News Today
jeudi 14 décembre 2017


Clinical Trials News From Medical News Today

Latest Clinical Trials News From Medical News Today.

Les derniers articles du site :
GPC Biotech Announces Start Of Phase 1 Trial Evaluating Satraplatin Plus Xeloda(R) In Patients With Advanced Solid Tumors
Mass. and PRINCETON, N.J. -- GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq: GPCB) today announced that a Phase 1 study evaluating the Company's lead drug candidate, satraplatin, in combination with Xeloda(R) (capecitabine) in patients with advanced solid tumors has opened (...)
jeudi 18 mai 2006
Pixantrone Produces High Rate (77 Percent) Of Complete Tumor Disappearance In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma
Preliminary results of a phase I/II study of pixantrone combined with fludarabine, dexamethasone, and rituximab for treatment of patients with relapsed indolent non-Hodgkin's lymphoma (NHL) will be presented today at the Rodman & Renshaw 3rd Annual Global Healthcare Conference in Monte Carlo, (...)
jeudi 18 mai 2006
Pharmion Announces Start Of Phase 1 Trial Evaluating Satraplatin Plus Xeloda(R) In Patients With Advanced Solid Tumors
Pharmion Corporation (Nasdaq: PHRM) today announced that a Phase 1 study evaluating satraplatin in combination with Xeloda(R) (capecitabine) in patients with advanced solid tumors has opened for accrual. Xeloda is an oral form of 5-FU, a marketed chemotherapy treatment that is used to treat (...)
jeudi 18 mai 2006
Progen Prepares For Accelerated Clinical Development Of Anti-Cancer PI-88 Following FDA Meeting
Progen Industries (Nasdaq: PGLAF; ASX: PGL) today announced it has received notification from the US Food and Drug Administration (FDA) guiding the accelerated development of its anti-cancer drug PI-88. The FDA has recommended that Progen submit a Special ProtocolAssessment (SPA) detailing the (...)
jeudi 18 mai 2006
Manhattan Pharmaceuticals Receives SwissMedic's Approval To Commence Phase IIa Trial With OE, Its Oral Obesity Drug Candidate
Manhattan Pharmaceuticals, Inc. (Amex: MHA) today reported receipt of Swiss regulatory approval to commence its Phase IIa study with oral Oleoyl-estrone (OE), the company's drug candidate for the treatment of obesity. The single center, Phase IIa study is a randomized, (...)
mercredi 17 mai 2006
Thoratec Receives FDA Approval Of Continued Access Protocol For Bridge Arm Of Its HeartMate(R) II Pivotal Trial
Thoratec Corporation (Nasdaq: THOR), a world leader in products to treatcardiovascular disease, today said that the FDA has approved an IDE(Investigational Device Exemption) supplement that allows enrollment of up to an additional 90 patients in the Bridge-to-Transplantation (BTT) arm of the (...)
mercredi 17 mai 2006
Preliminary 48-Week Results From Clinical Study Of HIV Protease Inhibitors Lexiva (Telzir) And Kaletra In Treatment-naive Patients With HIV
GlaxoSmithKline (GSK) and Vertex PharmaceuticalsIncorporated (Nasdaq: VRTX) today announced preliminary 48-week results from a head-to-head clinical study that indicated that Lexiva (Telzir; fosamprenavir calcium) 700 mg plus ritonavir 100 mg given twice daily was comparable (non-inferior) to (...)
mercredi 17 mai 2006
FDA Special Protocol Assessment, Agreement On Phase III Of Phenoxodiol As A Chemosensitizing Agent In Women With Platinum-Resistant Ovarian Cancer
Biotechnology company, Marshall Edwards, Inc., announced today that under the Special Protocol Assessment (SPA) process, it has reached agreement with the United States Food and Drug Administration (FDA) on the design of a pivotal study protocol for its investigational anti-cancer drug, (...)
mercredi 17 mai 2006
Moderate-Release TAXUS(R) Express(TM) Coronary Stent System Demonstrates Sustained Long-Term Outcomes In High-Risk Patients
Boston Scientific Corporation (NYSE: BSX) today announced three-year follow-up data from its TAXUS VI clinical trial. The data demonstrated that the safety and efficacy benefits associated with a moderate-release formulation of the TAXUS(R) Express(TM) paclitaxel-eluting stent system were (...)
mercredi 17 mai 2006
Leuprolide Acetate Stabilizes Cognitive And Functional Decline In Women With Alzheimer's Disease, Study Shows
Leuprolide acetate, when used in conjunction with standard Alzheimer's therapy, was shown to stabilize the cognitive and functional decline of women with mild-to-moderate Alzheimer's disease according to a Phase II study conducted by Voyager Pharmaceutical Corporation. [click link for full (...)
mercredi 17 mai 2006
Accueil     |    Plan du site     |    Espace rédacteurs     |    Se connecter
  Mis à jour le lundi 11 décembre 2017